Marengo to Showcase Pioneering Cancer Treatment at Upcoming Symposium
CAMBRIDGE, Mass. — Marengo Therapeutics, Inc., a cutting-edge biotechnology company specializing in precision immunotherapy, has exciting news for the oncology community. As part of its commitment to transforming cancer treatment, Marengo will deliver a significant late-breaking oral presentation at the forthcoming Society for Immunotherapy of Cancer (SITC) 2025 Annual Meeting, scheduled for early November 2025.
This presentation is poised to highlight the preliminary findings from the Phase 2 STARt-001 trial, which assesses the groundbreaking monotherapy Invikafusp alfa for tissue-agnostic and tumor mutational burden-high (TMB-H) advanced cancers. Early results indicate that Invikafusp alfa may activate specific T cell subsets, paving the way for enhanced anti-tumor immune responses in a variety of solid tumors.
Insightful Presentation Details to Anticipate
The forum promises to provide compelling data that could reshape the landscape of cancer immunotherapy. Here’s what attendees can expect:
Key Presentation Information
- Title: Initial monotherapy clinical activity of Invikafusp alfa in TMB-H patients from STARt-001, a Phase 1/2 trial
- Conference: SITC Annual Meeting 2025
- Abstract Number: LBA1316
- Session Title: Clinical Oral Abstract Session 1
- Date and Time: Friday, November 7, 2025, at 11:30 AM ET
- Presenter: Aurélien Marabelle, MD, PhD (Gustave Roussy Cancer Center, France)
Furthermore, Marengo will unveil data from its TriSTAR T cell engager platform and present four pioneering preclinical studies conducted in partnership with the National Cancer Institute (NCI). These analyses will explore innovative combinations of Invikafusp alfa with current standard therapies.
Understanding Marengo Therapeutics
Marengo Therapeutics, Inc. stands at the forefront of biotechnology as a clinical-stage company that is developing unique TCR-targeting antibodies. These antibodies have been shown to modulate specific T cell subsets aimed at providing enduring protection against cancer and autoimmune conditions. The company's dynamic team of scientists, with expertise in immunology and oncology, is driven by a vision to ensure every individual has the potential to utilize their immune system to combat cancer and related diseases.
Exploring the STAR™ Platform
The STAR™ Platform is a novel multi-specific antibody-fusion system derived from Marengo’s proprietary antibody library. This platform effectively targets germline-encoded V? regions of the TCR, allowing for the merging of T cell activation with co-stimulation in a single construct. It promises a unique mechanism of action that can stimulate lasting anti-tumor responses generally associated with V? T cells.
Detailed Look at Invikafusp alfa (STAR0602)
Invikafusp alfa (STAR0602) represents Marengo's lead candidate emerging from the STAR™ platform. The drug aims to activate a prevalent V? T cell subset present across various cancers. With its unique design that combines a non-clonal TCR activation method and T cell co-stimulation integrally, Invikafusp alfa seeks to enhance the capacity of effector memory V? T cells. This concrete mechanism is noted for its efficacy in generating anti-tumor immunity as evidenced in substantial preclinical studies involving mouse and human models.
Overview of the STARt-001 Clinical Study
STARt-001 is an extensive Phase 1/2 clinical trial dedicated to evaluating the safety and initial effectiveness of Invikafusp alfa as a standalone treatment in patients with advanced, antigen-rich solid tumors. The trial encompasses two key phases: the initial dose escalation followed by a subsequent dose expansion. Interested parties can seek further information on the trial and potential participation via clinicaltrials.gov (Identifier: NCT05592626).
For inquiries about participation specifically in the STARt-001 study at NCI, individuals can call NCI's toll-free number and find out more through their website.
Marengo Media Contacts:
Media: Peg Rusconi | [Email not displayed]
Investors: Svetlana Makhni | [Email not displayed]
Frequently Asked Questions
What is Marengo Therapeutics focused on?
Marengo Therapeutics specializes in developing innovative precision immunotherapies aimed at treating cancer and autoimmune diseases.
What significant finding will be presented at SITC 2025?
Marengo will showcase initial Phase 2 results of Invikafusp alfa, highlighting its potential effectiveness in treating advanced cancers.
What is the STAR™ Platform?
The STAR™ Platform is Marengo's unique multi-specific antibody fusion platform designed to target T cell activation and enhance anti-tumor responses.
What is Invikafusp alfa?
Invikafusp alfa (STAR0602) is Marengo's leading treatment candidate designed to activate specific T cell subsets for improved cancer immunity.
How can patients participate in the STARt-001 clinical trial?
Patients can find information on participation regarding the STARt-001 trial by visiting clinicaltrials.gov or contacting NCI directly.
